"The board will now start a formal search for a successor and will consider internal and external candidates for the role," said GlaxoSmithKline PLC's chair Sir Philip Hampton, and the games begin.
Witty's Successor: The Shortlist
"The board will now start a formal search for a successor and will consider internal and external candidates for the role," said GlaxoSmithKline PLC's chair Sir Philip Hampton, and the games begin.
More from Archive
More from Scrip
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
• By
Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.